RxDoctor Payments DataLook up a doctor →

Dale Lange, MD

Neurology · New York, NYNPI 1528038841

Payments from drug & device makers

$887,738in general payments, 2019–2025

Across 218 payments — averaging $4072.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$413K
  • Novartis$128K
  • Takeda Pharmaceuticals U.S.A., Inc.$93K
  • Orion Corporation$93K
  • AstraZeneca$65K
  • CSL Behring$33K
  • plus $62K from 11 others
$5,746in research payments, 2019–2025

Across 5 payments — averaging $1149.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$5K
  • AstraZeneca$546

What the payments were for

  • Consulting fees$10,80070%
  • Speaking & faculty fees$9006%
  • Travel & lodging$2,54017%
  • Food & beverage$1,1197%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$887,738 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$1,520,462
Medicare patients
68
Services billed
39,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4660$837,841
SolirisEculizumab14$725,898
GammakedImmune Globul G/Gly/Iga Avg 4612$443,868
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$354,374
OctagamImmun Globg(Igg)/Malt/Iga Ov5015$345,202
Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-5014$243,006
Carbidopa-LevodopaCarbidopa/Levodopa22$242
Prednisone15$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$14$837,84160 claims
AstraZenecaSoliris$65,488$725,89814 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$92,927$354,37413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →